Dx
Loading DxDepth…
DxDepth harnesses the latest medical literature and real-world evidence to deliver deep, evidence-based answers when clinical decisions matter most.
Medical Evidence
Real questions the product is built to answer — drawn from peer-reviewed literature and real-world evidence.
Adjuvant pembrolizumab duration in stage III NSCLC post-resection — 1 year vs beyond?
Trastuzumab deruxtecan in HER2-low metastatic breast cancer — who gets T-DXd first vs T-DM1?
Checkpoint inhibitor myocarditis workup — cardiac MRI vs endomyocardial biopsy?
Ipilimumab + nivolumab vs nivolumab alone in advanced melanoma — who benefits from dual IO?
Sacituzumab govitecan sequencing in metastatic TNBC — second-line vs post-progression?
Post-MI LVEF 32% — when to escalate to ICD vs wait out the 40-day remodeling window?
Where answers come from
DxDepth uniquely combines multiple sources of evidence to give you the most complete clinical picture.
Continuously indexed peer-reviewed journals, meta-analyses, and clinical studies — always up to date.
Insights drawn from real-world patient data, outcomes registries, and practice-based research networks.
Society guidelines and FDA guidance, indexed alongside the evidence — anchored to the standards clinicians answer to.
Verified physician community
Ask the questions that don't have a clean trial answer yet. Every post is HIPAA-moderated before publish, and our AI lays an evidence brief under each thread within seconds — so you discuss the decision, not the citation hunt.
Live questions
See all →GDMT sequencing in HFrEF when patient has CKD stage 3b — pillar order?
Cardiotoxicity surveillance with HER2-targeted therapy — strain echo cadence
First-line for HER2-low metastatic breast cancer — T-DXd vs chemo?
Join verified peers in your specialty across the US.
Sign upWhy DxDepth
Built for the moments where depth, provenance, and speed all matter at once.
Complex clinical questions distilled into clear, actionable insights — drawing on both literature and real-world data.
Designed for critical clinical decisions where evidence quality and depth directly impact patient outcomes.
Best-in-class answers in seconds, not hours of manual literature review — every claim traceable to its source.